Hematology/oncology clinics of North America
-
The elucidation of factors involved in the development of Wilms tumor represents a remarkable and fruitful marriage between epidemiology, clinical practice, histopathology, and molecular biology. Many fascinating research problems remain to be solved, and it is to be expected that the study of Wilms tumor will continue to yield valuable insights, not only in relation to Wilms tumor itself but also into tissue development and processes involved in malignant transformation in general.
-
Hematol. Oncol. Clin. North Am. · Oct 1995
Review Historical ArticleTopical treatment of early cutaneous T-cell lymphoma.
The two major topical treatment modalities for cutaneous T-cell lymphoma (CTCL) are mechlorethamine (nitrogen mustard) and topical carmustine (BCNU). Topical mechorethamine hydrochloride has been used since the late 1950s as therapy for CTCL. Topical BCNU solution is a highly effective treatment for early stage mycosis fungoides. This article describes these two modalities.
-
Hematol. Oncol. Clin. North Am. · Feb 1995
ReviewTransfusion-transmitted hepatitis virus infection.
For many years, viral hepatitis has been considered to be a frequent and serious adverse outcome of blood transfusion. The majority of cases have been due to hepatitis B and C viruses, which, respectively, are DNA and RNA viruses. Both are lipid enveloped and are susceptible to viral inactivation procedures. Careful donor screening and the use tests for HBsAg and anti-HBc have essentially eliminated the risk of transfusion-transmitted HBV infection.
-
Acquired coagulopathies, such as are observed in patients with liver disease, uremia, and acute disseminated intravascular coagulation, are complex disorders usually involving a combination of deficiency of multiple coagulation factors, platelet dysfunction, and thrombocytopenia. Transfusion of specific blood products, such as fresh-frozen plasma, platelets, and cryoprecipitate, may be effective in the treatment and prevention of hemorrhage in patients with these disorders; however, the optimal regimens continue to be defined. Because the risks of virus transmission along with hemolytic and allergic reactions continue to accompany blood product transfusions, nontransfusional forms of treatment of acquired coagulopathies, such as desmopressin acetate, antifibrinolytic agents, and aprotinin, have assumed greater roles in the treatment of these hemostatic disorders. Much work remains to define better the most effective and safest approach to the treatment of the acquired coagulopathies.